Canada markets open in 1 hour 59 minutes

Biofrontera Inc. (BFRI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8800-0.0200 (-1.05%)
At close: 04:00PM EDT
1.8300 -0.05 (-2.66%)
Pre-Market: 07:15AM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence

    Named Among the 10 Fastest-Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine New Ameluz® Marketing Campaign Receives Gold 2022 Award of Excellence from The Communicator Awards WOBURN, Mass, June 09, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company has been recognized for its contributions to the life sciences industry and for its newest Am

  • GlobeNewswire

    Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference

    WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in The Benchmark Healthcare House Call Virtual 1x1 Conference being held on June 2, 2022. Erica Monaco, Chief Executive Officer and Hermann Lübbert, Executive Chairman of Biofrontera Inc. will be meeting with registered investors in virtual one-on-one meetings and small

  • GlobeNewswire

    New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®

    WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin cancer prevalence provided by the American Cancer Society1, indicating approximately 3.4 million U.S. residents could be diagnosed with non-melanoma skin cancer (NMSC) in 2022, as strongly supportive of the commercial opportunity for the Company’s flagship product Ameluz®. Additionally, a market surve